Securities



Another disappointing quarter

Hai-O recorded a weak set of results. 9MFY19 core earnings declined 34% yoy to RM37.4m, which missed our and consensus expectations at for 68% and 62% of full-year estimates respectively. The MLM segment continued to underperform, as quarterly sales fell both sequentially (-11%) and yoy (-25%) while members' activity remains subdued. Margins also declined as a result, weighed down further by higher marketing costs. We maintain HOLD on Hai-O with a lower TP of RM2.50, after revising our EPS estimates lower as we turn less upbeat on its MLM segment's performance.

Below expectations

Hai-O's 9MFY19 core net profit declined 33.9% yoy to RM37.4m, mainly due to a sustained slump in MLM segment sales (-35.1% yoy) to RM177.5m which corresponded to a 30.9% fall in EBIT to RM36.3m. Lower intersegment sales from the Wholesale front also weighed on operating profit (-52.7% yoy), despite the segment recording a flattish 0.6% external top-line growth. Meanwhile, the Retail segment fared better as sales grew 11.4% yoy to RM31.0m, but nonetheless continued to be a minor earnings contributor.

Weaker sequentially

On a qoq basis, 3QFY19 earnings declined 6% vs. 2QFY19 to RM12.8m, underpinned by lower sequential sales from its MLM (-11% qoq) and Wholesale (-5.3% qoq) segments. In view of the MLM segment's subdued member activity as well as the challenging business environment currently seen, Hai-O's management intends to re-strategise its members' recruitment and retention plans, while moving towards "small-ticket" items at affordable price points.

Maintain HOLD with a lower TP of RM2.50

We cut our FY19-21E EPS estimates by -8.0%/-14.4%/-15.1% respectively to reflect our view of persisting challenges seen for its MLM segment, both in terms of its member base's activities, as well as reception for its product range. Following on, we derive a lower TP of RM2.50 after rolling forward our valuation base to FY20E, while based on an unchanged PER target of 13x. Maintain our HOLD recommendation on Hai-O. Upside/downside risks: i) strong/weak expansion in MLM distributor base; ii) better/lower-than-expected take-up rate of new products.

Earnings & Valuation Summary

Larinings & Valuation o	aiiiiiai y				
FYE 30 Apr	2017	2018	2019E	2020E	2021E
Revenue (RMm)	404.2	461.8	346.5	369.9	413.5
EBITDA (RMm)	81.1	105.6	69.3	75.5	86.4
Pretax profit (RMm)	78.3	99.0	66.2	72.4	83.3
Net profit (RMm)	59.4	75.4	50.5	55.3	63.5
EPS (sen)	20.4	25.9	17.4	19.0	21.8
PER (x)	13.2	10.4	15.5	14.2	12.4
Core net profit (RMm)	59.4	75.4	50.5	55.3	63.5
Core EPS (sen)	20.4	25.9	17.4	19.0	21.8
Core EPS growth (%)	63.3	27.0	(33.0)	9.4	15.0
Core PER (x)	13.2	10.4	15.5	14.2	12.4
Net DPS (sen)	16.0	20.0	11.3	12.3	14.2
Dividend Yield (%)	5.9	7.4	4.2	4.6	5.3
EV/EBITDA (x)	8.1	6.2	9.3	8.2	7.0
OL : EDO (0/)			(0.0)	(4.4.4)	(45.4)
Chg in EPS (%)			(8.0)	(14.4)	(15.1)
Affin/Consensus (x)			0.8	0.8	0.8
Source: Company Bloomborg A	ffin Hwana force	acto			

Source: Company, Bloomberg, Affin Hwang forecasts

Out think. Out perform.

Results Note

Hai-O

HAIO MK Sector: Consumer

RM2.70 @ 25 March 2019

HOLD (maintain)

Downside: 7%

Price Target: RM2.50 Previous Target: RM2.70



Price Performance

	1M	3M	12M
Absolute	-4.6%	5.5%	-42.6%
Rel to KLCI	-0.2%	7.7%	-35.0%

Stock Data

Issued shares (m)	290.4
Mkt cap (RMm)/(US\$m)	784/192.7
Avg daily vol - 6mth (m)	0.2
52-wk range (RM)	2.48-5.4
Est free float	55.3%
BV per share (RM)	1.03
P/BV (x)	2.62
Net cash/ (debt) (RMm)	117.8
ROE (2019E)	16.3%
Derivatives	Nil
Shariah Compliant	No

Key Shareholders

Kai Hee Tan	10.1%
Akintan Sdn Bhd	8.0%
Excellent Communication	5.4%
Exocutin Communication	0.470

Source: Affin Hwang, Bloomberg

Lester Siew (603) 2146 7502 lester.siew@affinhwang.com

Securities



Weaker sales in 3QFY19

Out think. Out perform.

MLM sales fell 11% qoq, off a higher base from 2QFY19's pre-26th anniversary and incentive trip sales campaign, alongside lower number of new members recruited. Wholesale sales declined 5.3% qoq due to higher CNY hamper sales offset by drop in sales of Chinese medicated tonic and patented medicine.

Fig 1: Results Comparison

FYE Apr (RMm)	3Q18	2Q19	3Q19	QoQ	YoY	9MFY18	9MFY19	YoY	Comments
				% chg	% chg			% chg	
Revenue	103.1	92.2	86.2	(6.5)	(16.4)	351.1	258.4	(26.4)	Significant 9MFY19 decline in MLM segment sales (-35.1% yoy), partially offset by 0.6% yoy and 11.4% yoy increase in Wholesale and Retail revenue respectively
Op costs	(79.5)	(72.9)	(68.2)	(6.4)	(14.1)	(275.3)	(206.0)	(25.2)	
EBITDA	23.6	19.2	17.9	(6.9)	(24.1)	75.8	52.5	(30.8)	
EBITDA margin (%)	22.9	20.9	20.8	-0.1ppt	-2.1ppt	21.6	20.3	-1.3ppt	
Depn and amort	(1.0)	(1.2)	(1.3)	2.7	23.7	(3.0)	(3.6)	22.5	
EBIT	22.6	18.0	16.7	(7.5)	(26.3)	72.9	48.8	(33.0)	
EBIT margin (%)	21.9	19.5	19.3	-0.2ppt	-2.6ppt	20.7	18.9	-1.9ppt	Lower recorded sales alongside higher marketing and branding costs, despite a 1.8pp gross margin improvement or better sales mix.
Int expense	(0.0)	(0.0)	(0.0)	28.0	(8.6)	(0.1)	(0.1)	(0.9)	
Int and other inc	0.5	0.3	0.3	3.2	(37.3)	1.2	0.9	(27.8)	
Associates	0.0	0.0	0.0	n.m.	n.m.	0.0	0.0	n.m.	
Exceptional items	0.0	0.0	0.0	n.m.	n.m.	0.0	0.0	n.m.	
Pretax	23.0	18.3	16.9	(7.3)	(26.5)	74.0	49.6	(32.9)	
Tax	(5.8)	(4.4)	(4.1)	(6.4)	(28.9)	(17.5)	(12.3)	(29.8)	
Tax rate (%)	25.2	24.1	24.4	0.2ppt	-0.8ppt	23.7	24.8	1.1ppt	
MI	0.0	(0.3)	(0.0)	n.m.	n.m.	0.1	0.1	n.m.	
Net profit	17.3	13.6	12.8	(6.0)	(25.9)	56.6	37.4	(33.9)	
EPS (sen)	5.9	4.7	4.4	(6.0)	(25.9)	19.4	12.9	(33.9)	
Core net profit	17.3	13.6	12.8	(6.0)	(25.9)	56.6	37.4	(33.9)	Below our and consensus estimates, accounting for 68% and 62% of full-year forecasts

Source: Affin Hwang, Company data

Fig 2: Segmental Breakdown

ig 21 cogmonar 2 contactin	3Q18	2Q19	3Q19	QoQ % chg	YoY % chg
Segmental Revenue					
MLM	75.42	63.16	56.27	(10.92)	(25.40)
Wholesale	17.12	17.14	16.22	(5.32)	(5.23)
Retail	9.32	10.83	12.55	15.90	34.68
Others	1.09	1.05	1.12	7.08	2.85
Total revenue	103.07	92.17	86.16	(6.53)	(16.41)
Segmental Profit					
MLM	14.15	14.02	11.88	(15.25)	(16.02)
Wholesale	9.09	3.06	3.08	0.79	(66.10)
Retail	0.13	0.57	0.46	(19.41)	251.91
Others	1.47	0.99	1.40	41.53	(4.23)
	24.57	18.01	16.65	(7.54)	(26.28)

Source: Affin Hwang, Company data

Securities



Important Disclosures and Disclaimer

Out think. Out perform.

Equity Rating Structure and Definitions

BUY Total return is expected to exceed +10% over a 12-month period

HOLD Total return is expected to be between -5% and +10% over a 12-month period

SELL Total return is expected to be below -5% over a 12-month period

NOT RATED Affin Hwang Investment Bank Berhad does not provide research coverage or rating for this company. Report is intended as information

only and not as a recommendation

The total expected return is defined as the percentage upside/downside to our target price plus the net dividend yield over the next 12 months.

OVERWEIGHT Industry, as defined by the analyst's coverage universe, is expected to outperform the KLCI benchmark over the next 12 months

NEUTRAL Industry, as defined by the analyst's coverage universe, is expected to perform inline with the KLCI benchmark over the next 12 months

UNDERWEIGHT Industry, as defined by the analyst's coverage universe is expected to under-perform the KLCI benchmark over the next 12 months

This report is intended for information purposes only and has been prepared by Affin Hwang Investment Bank Berhad (14389-U) ("the Company") based on sources believed to be reliable and is not to be taken in substitution for the exercise of your judgment. You should obtain independent financial, legal, tax or such other professional advice, when making your independent appraisal, assessment, review and evaluation of the company/entity covered in this report. However, such sources have not been independently verified by the Company, and as such the Company does not give any guarantee, representation or warranty (expressed or implied) as to the adequacy, accuracy, reliability or completeness of the information and/or opinion provided or rendered in this report. Facts, information, estimates, views and/or opinion presented in this report have not been reviewed by, may not reflect information known to, and may present a differing view expressed by other business units within the Company, including investment banking personnel and the same are subject to change without notice. Reports issued by the Company, are prepared in accordance with the Company's policies for managing conflicts of interest. Under no circumstances shall the Company, be liable in any manner whatsoever for any consequences (including but are not limited to any direct, indirect or consequential losses, loss of profit and damages) arising from the use of or reliance on the information and/or opinion provided or rendered in this report. Under no circumstances shall this report be construed as an offer to sell or a solicitation of an offer to buy any securities. The Company its directors, its employees and their respective associates may have positions or financial interest in the securities mentioned therein. The Company, its directors, its employees and their respective associates may have positions or financial interest in the securities mentioned therein. The Company, its directors, its employees and their respective associates, may provide, or ha

Third-party data providers make no warranties or representations of any kind relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages of any kind relating to such data.

This report, or any portion thereof may not be reprinted, sold or redistributed without the written consent of the Company

This report is printed and published by: Affin Hwang Investment Bank Berhad (14389-U) A Participating Organisation of Bursa Malaysia Securities Berhad

22nd Floor, Menara Boustead, 69, Jalan Raja Chulan, 50200 Kuala Lumpur, Malaysia.

T:+603 2142 3700 F:+603 2146 7630 research@affinhwang.com

www.affinhwang.com